Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/RHU.0b013e31823262c3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis.
Case Rep Dermatol
May 2017
aDepartment of Dermatology, Shonan Fujisawa Tokushukai Hospital, Fujisawa, Japan.
A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled. However, after 21 doses of infliximab, the skin lesions and joint pain exacerbated and became intractable.
View Article and Find Full Text PDFExacerbation of infliximab-induced paradoxical psoriasis after ustekinumab therapy.
J Dermatol
March 2018
Department of Dermatology, National Medical Center, Seoul, Korea.
Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
Scand J Gastroenterol
November 2016
b Helsinki University Hospital, Children's Hospital and Helsinki University, Helsinki , Finland.
Objective: The use of infliximab in rheumatoid and inflammatory bowel diseases (IBD) has been associated with a variety of adverse skin reactions, including paradoxical psoriatic lesions. The prevalence and possible predictors for these lesions were under observation in our cross-sectional prospective study.
Material And Methods: Nurses screened the skin of 118 adult patients with IBD during infliximab infusions between 4 September 2013 and 30 September 2014 based on the structured questionnaire.
Nephrotic syndrome after infliximab treatment in a patient with ulcerative colitis.
J Gastrointestin Liver Dis
June 2015
Department of Gastroenterology, IBD and Nutrition Support, Beaujon Hospital, Paris VII University, Clichy, France.
Tumor necrosis factor (TNF)-targeted therapies are increasingly used to treat a variety of inflammatory and autoimmune diseases. They are now used worldwide, and this class of medication has revolutionized the treatment of these diseases and the quality of life for patients but it also poses risk of developing various side effects including infections, exacerbation of some neurological manifestations, cutaneous lesions or induces antibody production. Renal complications are uncommon and poorly recognized.
View Article and Find Full Text PDFThe onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
Arq Gastroenterol
December 2012
Division of Coloproctology, Department of Surgery, School of Medical Sciences, State University of São Paulo (UNESP), Botucatu, SP, Brazil.
Context: Several paradoxical cases of infliximab-induced or-exacerbated psoriatic lesions have been described in the recent years. There is disagreement regarding the need to discontinue infliximab in order to achieve the resolution of these adverse cutaneous reactions specifically in inflammatory bowel disease (IBD) patients.
Objective: To systematically review the literature to collect information on IBD patients that showed this adverse cutaneous reaction, focusing mainly on the therapeutic approach.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!